LCM
AXSM icon

Legato Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Legato Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.56M Buy
18,644
+3,106
+20% +$674K 0.38% 49
2026
Q1 		$2.63M Buy
15,538
+5,911
+61% +$1.02M 0.24% 118
2025
Q4 		$1.76M Buy
9,627
+4,576
+91% +$639K 0.15% 211
2025
Q3 		$613K Buy
5,051
+750
+17% +$84.5K 0.07% 414
2025
Q2 		$449K Sell
4,301
-5,680
-57% -$601K 0.05% 452
2025
Q1 		$1.16M Buy
+9,981
New +$1.14M 0.16% 211
2024
Q2 		– Sell
-4,733
Closed -$378K – 564
2024
Q1 		$378K Sell
4,733
-3,889
-45% -$326K 0.05% 481
2023
Q4 		$686K Hold
8,622
– – 0.09% 350
2023
Q3 		$603K Sell
8,622
-3,330
-28% -$249K 0.09% 355
2023
Q2 		$859K Buy
11,952
+4,925
+70% +$363K 0.12% 291
2023
Q1 		$433K Hold
7,027
– – 0.08% 379
2022
Q4 		$542K Buy
+7,027
New +$420K 0.1% 329

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Legato Capital Management's AXSM Position: Q2 2026 in Review

Legato Capital Management increased its Axsome Therapeutics (AXSM) stake by 20% in Q2 2026, buying an estimated $674K and bringing the position to 18,644 shares worth $4.56M. The position accounts for 0.38% of the portfolio, ranked #49.

Legato Capital Management first reported a position in AXSM in Q4 2022 and has held it in 12 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Legato Capital Management held 18,644 shares of Axsome Therapeutics worth $4.56M as of Q2 2026.
  • Legato Capital Management bought 3,106 Axsome Therapeutics shares in Q2 2026, an estimated $674K.
  • Axsome Therapeutics made up 0.38% of Legato Capital Management's portfolio in Q2 2026, its #49 holding.
  • Legato Capital Management first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 12 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.